SCHEMBL3564569

SCHEMBL3564569

CC(C)c1ccc(S(=O)(=O)n2c(-c3ccccc3)c(OCCN(C)C)c3cc(Cl)cc(Br)c32)cc1

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PSEN1 P49768 2/20 0.34
PSEN2 P49810 2/20 0.34
APH1B Q8WW43 2/20 0.34
NCSTN Q92542 2/20 0.34
APH1A Q96BI3 2/20 0.34
PSENEN Q9NZ42 2/20 0.34
NOD1 Q9Y239 1/20 0.34
PHGDH O43175 1/20 0.34
HTR6 P50406 5/20 0.33
KDM4E B2RXH2 2/20 0.32
ALDH1A1 P00352 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
TACR3 P29371 1/20 0.32
ACLY P53396 1/20 0.32
CSF1R P07333 1/20 0.32
HTR7 P34969 1/20 0.31
ADORA2A P29274 1/20 0.31
ADORA1 P30542 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3563972 0.93 HTR6 (0.38) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL3558834 0.93 HTR6 (0.36) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL3564860 0.92 HTR6 (0.37) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL3556312 0.92 KDM4E (0.36) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL3562380 0.91 PSEN1 (0.35) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL3553560 0.91 AGTR1 (0.38) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL3561685 0.90 HTR6 (0.42) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL3563419 0.87 HTR6 (0.37) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL3926700 0.87 HTR6 (0.35) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL3569613 0.86 HTR6 (0.38) HTR6KDM4EALDH1A1SMN1; SMN2ACLY

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1567492-B1 N-ARYLSULFONYL-3-AMINOALKOXYINDOLES SUVEN LIFE SCIENCES LTD (IN) 2013-05-22 EP claimed
US-7507835-B2 N-arylsulfonyl-3-aminoalkoxyindoles SUVEN LIFE SCIENCES LTD. (IN) 2009-03-24 US claimed
US-20060173193-A1 N-arylsulfonyl-3-aminoalkoxyindoles SUVEN LIFE SCIENCES LIMITED (IN) 2006-08-03 US claimed
EP-1567492-A2 N-ARYLSULFONYL-3-AMINOALKOXYINDOLES Suven Life Sciences Limited (IN) 2005-08-31 EP claimed
WO-2004048328-A2 N-ARYLSULFONYL-3-AMINOALKOXYINDOLES SUVEN LIFE SCIENCES LIMITED (IN) 2004-06-10 WO claimed
EP-1567492-B1 N-ARYLSULFONYL-3-AMINOALKOXYINDOLES SUVEN LIFE SCIENCES LTD (IN) 2013-05-22 EP disclosed
US-7718690-B2 N-arylsulfonyl-3-aminoalkoxyindoles RAMAKRISHNA VENKATA SATYA NIROGI 2010-05-18 US disclosed
US-20090131507-A1 N-arylsulfonyl-3-aminoalkoxyindoles SUVEN LIFE SCIENCES LIMITED (IN) 2009-05-21 US disclosed
US-7507835-B2 N-arylsulfonyl-3-aminoalkoxyindoles SUVEN LIFE SCIENCES LTD. (IN) 2009-03-24 US disclosed
US-20060173193-A1 N-arylsulfonyl-3-aminoalkoxyindoles SUVEN LIFE SCIENCES LIMITED (IN) 2006-08-03 US disclosed
EP-1567492-A2 N-ARYLSULFONYL-3-AMINOALKOXYINDOLES Suven Life Sciences Limited (IN) 2005-08-31 EP disclosed
WO-2004048328-A2 N-ARYLSULFONYL-3-AMINOALKOXYINDOLES SUVEN LIFE SCIENCES LIMITED (IN) 2004-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131507-A1 N-arylsulfonyl-3-aminoalkoxyindoles HTR3C, HTR3A, AANAT PSEN1 3387/4885PSEN2 2402/4885APH1B 4349/4885
US-20060173193-A1 N-arylsulfonyl-3-aminoalkoxyindoles HTR3C, HTR3A, AANAT PSEN1 3387/4885PSEN2 2402/4885APH1B 4349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.